SGLT2阻害薬が糖尿病合併非アルコール性脂肪性肝疾患に及ぼす影響―連続肝生検診断に基づく前向き試験―

DOI Web Site Web Site 被引用文献1件 参考文献4件

書誌事項

タイトル別名
  • Impact of sodium-glucose co-transporter 2 inhibitor for non-alcoholic fatty liver disease complicated by diabetes mellitus -Prospective study based on the serial liver biopsy-
  • SGLT2 ソガイヤク ガ トウニョウビョウ ガッペイ ヒアルコールセイ シボウセイ カン シッカン ニ オヨボス エイキョウ : レンゾク カンセイケンシンダン ニ モトズク マエムキ シケン

この論文をさがす

抄録

<p>A prospective study based on the serial liver biopsy was performed to investigate the efficacy of sodium-glucose co-transporter 2 (SGLT2) inhibitor for NAFLD complicated by type 2 diabetes mellitus. 2 patients were introduced the regimen of canagliflozin 100 mg once daily for 24 weeks, and could be evaluated liver histology at the two points of the pretreatment and 24 weeks after the start of treatment. In both of patients, hepatocyte steatosis grade and NAFLD activity score improved at 24 weeks, compared to the pretreatment. Furthermore, physical examination, glucose metabolism, serum ferritin levels, and findings of transient elastography also improved. In conclusion, a prospective study based on the serial liver biopsy indicated that SGLT2 inhibitor for NAFLD complicated by diabetes mellitus improved hepatocyte steatosis. Further large-scale and long-term studies are needed to determine the impact of SGLT2 inhibitor for histological features, including fibrosis stage.</p>

収録刊行物

  • 肝臓

    肝臓 57 (9), 502-504, 2016

    一般社団法人　日本肝臓学会

被引用文献 (1)*注記

もっと見る

参考文献 (4)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ